

# Philip Choi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079319/publications.pdf>

Version: 2024-02-01

18  
papers

309  
citations

1163117

8  
h-index

940533

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. <i>Haematologica</i> , 2015, 100, 623-632.	3.5	84
2	A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). <i>Blood</i> , 2015, 126, 500-503.	1.4	60
3	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2022, 386, 1421-1431.	27.0	52
4	Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. <i>Medical Journal of Australia</i> , 2021, 215, 245.	1.7	29
5	A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 3494-3506.	5.2	17
6	Novel scientific approaches and future research directions in understanding ITP. <i>Platelets</i> , 2020, 31, 315-321.	2.3	13
7	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
8	R2 and R2* MRI assessment of liver iron content in an undifferentiated diagnostic population with hyperferritinaemia, and impact on clinical decision making. <i>European Journal of Radiology</i> , 2021, 135, 109473.	2.6	10
9	Presentation and outcome of idiopathic thrombocytopenic purpura in a single Australian centre. <i>Internal Medicine Journal</i> , 2012, 42, 841-845.	0.8	9
10	Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. <i>Medical Journal of Australia</i> , 2022, 216, 43-52.	1.7	8
11	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 14-14.	1.4	5
12	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2094-2095.	3.8	4
13	Altitude exposure as a training & iron overload management strategy post leukemia. <i>Journal of Science and Medicine in Sport</i> , 2020, 23, 75-81.	1.3	2
14	Alemtuzumab induced red cell aplasia and other immune cytopenias â€not so â€pureâ€™. <i>Immunotherapy</i> , 2021, , .	2.0	2
15	The molecular basis of immune-based platelet disorders. <i>Clinical Science</i> , 2020, 134, 2807-2822.	4.3	1
16	SkMâ€ing information from traumatized tissue. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1306-1308.	3.8	1
17	Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone. <i>Case Reports in Hematology</i> , 2017, 2017, 1-2.	0.4	0
18	Lifting the fog over ITP. <i>Platelets</i> , 2020, 31, 283-284.	2.3	0